{
  "prompt": {
    "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless specifically for symptom relief, as it does not improve perinatal outcomes.  \n   Reason: The guideline states \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\" and \"Ursodeoxycholic acid may reduce maternal itch but does not significantly impact perinatal outcomes.\"  \n\n2. **Different management plan** - Re-evaluate the need for twice-weekly CTGs and weekly growth scans, as these do not predict or prevent stillbirth in ICP.  \n   Reason: The guideline explicitly states \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP.\"  \n\n3. **Improved patient advice** - Counsel the patient more explicitly about the lack of evidence for UDCA in improving pregnancy outcomes, while acknowledging its potential for symptom relief.  \n   Reason: The guideline emphasizes that treatments do not improve pregnancy outcomes, and patient counseling should reflect this.  \n\n### Somewhat Important Recommendations\n1. **Additional information needed** - Document whether baseline bile acid levels were checked at booking, as this is recommended for future reference in subsequent pregnancies.  \n   Reason: The guideline recommends \"In subsequent pregnancies, baseline measurement of liver function tests and bile acid concentrations should be performed to establish normal levels.\"  \n\n2. **Different management plan** - Consider discussing severe or atypical cases with a hepatologist, though this case does not currently appear severe.  \n   Reason: The guideline advises \"Specialist hepatology advice should be sought for severe, very early, or atypical presentations of ICP.\"  \n\n3. **Improved patient advice** - Provide clearer information on the increased risk of pre-eclampsia and gestational diabetes, and ensure monitoring for these conditions.  \n   Reason: The guideline states \"Women with ICP have a higher chance of developing pre-eclampsia or gestational diabetes. They should have regular monitoring for these conditions.\"  \n\n### Less Important Recommendations\n1. **Additional information needed** - Consider documenting a more detailed social history regarding support systems postpartum, given the increased risk of neonatal care needs.  \n   Reason: The guideline notes that women with ICP have a higher chance of their baby requiring neonatal care.  \n\n2. **Improved patient advice** - Offer written information on ICP Support and RCOG resources for further reading.  \n   Reason: The guideline lists \"Information for women and families from ICP Support and RCOG\" as a useful resource.  \n\n### Unimportant Recommendations\n1. **Additional information needed** - Document whether the patient has a family history of hepatobiliary diseases, though this is not critical for management.  \n   Reason: The guideline mentions a small increased chance of hepatobiliary diseases later in life, but this does not impact current management.  \n\n2. **Improved patient advice** - Consider discussing long-term follow-up for hepatobiliary and immune-mediated diseases, though this is less urgent.  \n   Reason: The guideline notes a small increased lifetime risk, but this is not a focus of acute management.  \n\n### Summary of Key Adjustments Needed:\n- **De-emphasize UDCA** unless the patient prioritizes symptom relief over unproven perinatal benefits.  \n- **Reduce fetal surveillance intensity** (e.g., CTGs/growth scans) unless other indications exist, as they do not prevent stillbirth in ICP.  \n- **Strengthen counseling** on risks (e.g., pre-eclampsia, gestational diabetes) and realistic expectations of treatments.  \n- **Align delivery timing** with bile acid levels (e.g., earlier delivery if ≥100 µmol/L) as the primary risk-stratification tool.  \n\nThese changes would better align the note with the 2022 BJOG guideline’s emphasis on avoiding unnecessary interventions while focusing on bile acid–guided delivery timing and symptom management.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 56 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
    "transcript_length": 3421,
    "analysis_length": 4360,
    "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
    "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid 500 mg BID only if patient prioritizes symptom relief, after discussing its limited impact on perinatal outcomes.\",\n      \"context\": \"Guideline states UDCA should not be routinely offered for perinatal outcomes as it only provides symptom relief\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Reassess need for intensive surveillance as CTGs/growth scans do not prevent stillbirth in ICP\",\n      \"context\": \"Guideline states these monitoring methods do not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Discussed nature of obstetric cholestasis, including explicit counseling about UDCA's limited impact on pregnancy outcomes and increased risks of pre-eclampsia/gestational diabetes\",\n      \"context\": \"Guideline emphasizes need for realistic treatment expectations and comprehensive risk counseling\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Counseling should reflect that treatments do not improve pregnancy outcomes\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document whether baseline bile acid levels were checked at booking for future reference\",\n      \"context\": \"Guideline recommends establishing baseline levels for subsequent pregnancies\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"In subsequent pregnancies, baseline measurement of bile acid concentrations should be performed\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Provided written information and contact details for triage if symptoms worsen.\",\n      \"suggestedText\": \"Provided written information including ICP Support and RCOG resources along with triage contacts\",\n      \"context\": \"Guideline lists these as recommended patient resources\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Information for women and families from ICP Support and RCOG\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"No documented...fetal growth scan within the last 2 weeks\",\n      \"suggestedText\": \"Consider documenting rationale for any growth scans ordered, as routine scans are not recommended for ICP monitoring\",\n      \"context\": \"Growth scans not indicated for ICP monitoring per guideline\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Fetal ultrasound...do not predict or prevent stillbirth in ICP\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-10T20-59-03",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\\n Patient Details:\\nName: [Fictional Name] Sarah Ahmed\\n\\n\\nAge: 32\\n\\n\\nBMI: 24.7 (weight 68 kg, height 1.66 m)\\n\\n\\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\\n\\n\\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\\n\\n\\nBooking bloods and anomaly scans: Unremarkable\\n\\n\\nHistory of Presenting Complaint:\\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\\nRelevant Obstetric History:\\nPrevious pregnancy uncomplicated; term vaginal delivery.\\n\\n\\nNo history of intrahepatic cholestasis in prior pregnancy.\\n\\n\\nNo history of preterm labour or hypertensive disorders.\\n\\n\\nRelevant Medical History:\\nMild childhood asthma (not on regular treatment).\\n\\n\\nNo known liver or gallbladder disease.\\n\\n\\nMedications & Allergies:\\nCurrently taking ferrous fumarate and pregnancy multivitamin.\\n\\n\\nNo known drug allergies.\\n\\n\\nSocial History:\\nLives with husband and toddler son.\\n\\n\\nNon-smoker; does not consume alcohol.\\n\\n\\nWorks part-time as a dental nurse; currently on maternity leave.\\n\\n\\nExamination Findings:\\nGeneral: Alert and well, no jaundice noted.\\n\\n\\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\\n\\n\\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\\n\\n\\nNo uterine tenderness or signs of labour.\\n\\n\\nNo peripheral oedema; BP 118/74 mmHg.\\n\\n\\nNotable Omissions (for testing purposes):\\nNo documented baseline bile acid levels from booking bloods.\\n\\n\\nNo record of fetal growth scan within the last 2 weeks.\\n\\n\\nNo documentation of CTG to assess current fetal wellbeing.\\n\\n\\nImpression:\\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\\nManagement Plan:\\nInvestigations:\\n\\n\\nSerum bile acids and liver function tests (LFTs) urgently.\\n\\n\\nFasting bile acids if initial results are borderline.\\n\\n\\nFull blood count and clotting screen (due to potential risk of coagulopathy).\\n\\n\\nCTG to assess fetal wellbeing.\\n\\n\\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\\n\\n\\nMedical Management:\\n\\n\\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\\n\\n\\nConsider chlorphenamine for symptomatic relief of itching.\\n\\n\\nOngoing Care and Delivery Planning:\\n\\n\\nWeekly bile acids and LFTs.\\n\\n\\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\\n\\n\\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\\n\\n\\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\\n\\n\\nCounseling Provided:\\n\\n\\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\\n\\n\\nReassured about ongoing monitoring and early delivery plan.\\n\\n\\nAdvised to monitor fetal movements closely and report any reduction.\\n\\n\\nProvided written information and contact details for triage if symptoms worsen.\\n\\n\\nDictated by: Dr. [Fictional Name] Patel\\n Date: [Fictional Date]\\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\\n\\n\\n\\nGuideline Analysis:\\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless specifically for symptom relief, as it does not improve perinatal outcomes.  \\n   Reason: The guideline states \\\"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\\\" and \\\"Ursodeoxycholic acid may reduce maternal itch but does not significantly impact perinatal outcomes.\\\"  \\n\\n2. **Different management plan** - Re-evaluate the need for twice-weekly CTGs and weekly growth scans, as these do not predict or prevent stillbirth in ICP.  \\n   Reason: The guideline explicitly states \\\"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP.\\\"  \\n\\n3. **Improved patient advice** - Counsel the patient more explicitly about the lack of evidence for UDCA in improving pregnancy outcomes, while acknowledging its potential for symptom relief.  \\n   Reason: The guideline emphasizes that treatments do not improve pregnancy outcomes, and patient counseling should reflect this.  \\n\\n### Somewhat Important Recommendations\\n1. **Additional information needed** - Document whether baseline bile acid levels were checked at booking, as this is recommended for future reference in subsequent pregnancies.  \\n   Reason: The guideline recommends \\\"In subsequent pregnancies, baseline measurement of liver function tests and bile acid concentrations should be performed to establish normal levels.\\\"  \\n\\n2. **Different management plan** - Consider discussing severe or atypical cases with a hepatologist, though this case does not currently appear severe.  \\n   Reason: The guideline advises \\\"Specialist hepatology advice should be sought for severe, very early, or atypical presentations of ICP.\\\"  \\n\\n3. **Improved patient advice** - Provide clearer information on the increased risk of pre-eclampsia and gestational diabetes, and ensure monitoring for these conditions.  \\n   Reason: The guideline states \\\"Women with ICP have a higher chance of developing pre-eclampsia or gestational diabetes. They should have regular monitoring for these conditions.\\\"  \\n\\n### Less Important Recommendations\\n1. **Additional information needed** - Consider documenting a more detailed social history regarding support systems postpartum, given the increased risk of neonatal care needs.  \\n   Reason: The guideline notes that women with ICP have a higher chance of their baby requiring neonatal care.  \\n\\n2. **Improved patient advice** - Offer written information on ICP Support and RCOG resources for further reading.  \\n   Reason: The guideline lists \\\"Information for women and families from ICP Support and RCOG\\\" as a useful resource.  \\n\\n### Unimportant Recommendations\\n1. **Additional information needed** - Document whether the patient has a family history of hepatobiliary diseases, though this is not critical for management.  \\n   Reason: The guideline mentions a small increased chance of hepatobiliary diseases later in life, but this does not impact current management.  \\n\\n2. **Improved patient advice** - Consider discussing long-term follow-up for hepatobiliary and immune-mediated diseases, though this is less urgent.  \\n   Reason: The guideline notes a small increased lifetime risk, but this is not a focus of acute management.  \\n\\n### Summary of Key Adjustments Needed:\\n- **De-emphasize UDCA** unless the patient prioritizes symptom relief over unproven perinatal benefits.  \\n- **Reduce fetal surveillance intensity** (e.g., CTGs/growth scans) unless other indications exist, as they do not prevent stillbirth in ICP.  \\n- **Strengthen counseling** on risks (e.g., pre-eclampsia, gestational diabetes) and realistic expectations of treatments.  \\n- **Align delivery timing** with bile acid levels (e.g., earlier delivery if ≥100 µmol/L) as the primary risk-stratification tool.  \\n\\nThese changes would better align the note with the 2022 BJOG guideline’s emphasis on avoiding unnecessary interventions while focusing on bile acid–guided delivery timing and symptom management.\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 56 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nPlease extract actionable suggestions from this analysis and format them as specified.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"brief explanation of why this change is suggested\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Keep context explanations concise but informative\\n- Prioritize suggestions based on clinical importance\\n- If no specific suggestions can be made, return {\\\"suggestions\\\": []}\",\n  \"transcript_length\": 3421,\n  \"analysis_length\": 4360,\n  \"guideline_id\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\",\n  \"guideline_title\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid 500 mg BID only if patient prioritizes symptom relief, after discussing its limited impact on perinatal outcomes.\",\n      \"context\": \"Guideline states UDCA should not be routinely offered for perinatal outcomes as it only provides symptom relief\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Reassess need for intensive surveillance as CTGs/growth scans do not prevent stillbirth in ICP\",\n      \"context\": \"Guideline states these monitoring methods do not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Discussed nature of obstetric cholestasis, including explicit counseling about UDCA's limited impact on pregnancy outcomes and increased risks of pre-eclampsia/gestational diabetes\",\n      \"context\": \"Guideline emphasizes need for realistic treatment expectations and comprehensive risk counseling\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Counseling should reflect that treatments do not improve pregnancy outcomes\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document whether baseline bile acid levels were checked at booking for future reference\",\n      \"context\": \"Guideline recommends establishing baseline levels for subsequent pregnancies\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"In subsequent pregnancies, baseline measurement of bile acid concentrations should be performed\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Provided written information and contact details for triage if symptoms worsen.\",\n      \"suggestedText\": \"Provided written information including ICP Support and RCOG resources along with triage contacts\",\n      \"context\": \"Guideline lists these as recommended patient resources\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Information for women and families from ICP Support and RCOG\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"No documented...fetal growth scan within the last 2 weeks\",\n      \"suggestedText\": \"Consider documenting rationale for any growth scans ordered, as routine scans are not recommended for ICP monitoring\",\n      \"context\": \"Growth scans not indicated for ICP monitoring per guideline\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Fetal ultrasound...do not predict or prevent stillbirth in ICP\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 2036\nCompletion tokens: 710\nTotal tokens: 2746\nEstimated cost: $0.001373",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 2036,
    "completion_tokens": 710,
    "total_tokens": 2746,
    "estimated_cost_usd": 0.001373
  }
}